EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesMELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer, including focal, subtotal, and whole-gland treatment approaches. These initiatives reflect Telix’s commitment to advancing the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research activities and physician education focused on the combination of EDAP’s Focal One Robotic HIFU and Telix’s PSMA PET imaging products in the management of prostate cancer.
EDAP | Focal One to Host Investor Day on June 1, 2026, May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026
EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026
EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services ConferenceEDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference
EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026
EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue GuidanceEDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance
EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFUEDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU
EDAP to Present at Piper Sandler 37th Annual Healthcare ConferenceEDAP to Present at Piper Sandler 37th Annual Healthcare Conference
EDAP Reports Third Quarter 2025 Financial ResultsEDAP Reports Third Quarter 2025 Financial Results
EDAP to Present at Jefferies Global Healthcare Conference in LondonEDAP to Present at Jefferies Global Healthcare Conference in London
EDAP to Participate in the UBS Global Healthcare Conference EDAP to Participate in the UBS Global Healthcare Conference
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment OptionFocal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option
EDAP Receives HIFU Reimbursement for Prostate Cancer in FranceAUSTIN, Texas, September 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that the French Ministry of Health has awarded reimbursement for High Intensity Focused Ultrasound (HIFU) procedure for the treatment of prostate cancer in France. Reimbursement in France will specifically cover use of the Focal One Robotic HIFU procedure for eligible patients as a primary treatment of localized prostate cancer as well as a salvage treatment option following radiotherapy.
EDAP Reports Strong Second Quarter 2025 HIFU Results Company to Host Conference Call and Webcast Today, August 28th, at 8:30 a.m. EDT
